Additional small molecules may come into play for future SCI therapies…

The complexity of spinal cord injury makes therapeutic strategies increasingly difficult when attempting to bring about functional recovery. Two of the biggest hurdles to overcome has been the glial scar and adult neurons needing to extend very long axons and make synapses. I’ve blogged extensively about the ability of Chondroitinase ABC to overcome glial scar and its path to clinical application. We’ve also closely watched the genetic deletion of PTEN in neuron regeneration. With animal studies so far, it is still not possible to apply these invasive strategies to humans. There is ongoing work with easily deliverable reagents that target both the glial scar and PTEN pathway.

I’ve supplied information with ongoing peptide study abstracts and video’s where CSPG has been overcome by a receptor first discovered in the Frank Longo Lab and being worked on in the Silver lab at Case Western Reserve University. Myelinating strategies for oligodendrocytes and avoiding cell death is also an option with easy to deliver small molecules. It’s worth keeping an eye on these strategies and upcoming animal study results since these options would surely be a bit easier to get through the FDA and are translatable.

Oral Administration of a Small Molecule Targeted to Block proNGF Binding to p75 Promotes Myelin Sparing and Functional Recovery after Spinal Cord Injury.


This entry was posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research. Bookmark the permalink.